It was demonstrated that in patients with advanced esophageal squamous cell carcinoma [8] and in those with advanced gastric cancer [18], the RPN2-negative group had better pathological and clinical responses to docetaxel-based chemotherapy than the RPN2-positive group. This evidence concerns the gene RPN2 and esophageal squamous cell carcinoma.